Published in J Gen Microbiol on April 01, 1984
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Invalidity for Pseudomonas aeruginosa of an accepted model of bacterial permeability to beta-lactam antibiotics. Antimicrob Agents Chemother (1991) 1.37
Multiply resistant mutants of Enterobacter cloacae selected by beta-lactam antibiotics. Antimicrob Agents Chemother (1986) 1.34
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2009) 1.07
Pseudomonas aeruginosa AlgR controls cyanide production in an AlgZ-dependent manner. J Bacteriol (2009) 0.86
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Typing of Pseudomonas pyocyanea by pyocine production. J Pathol Bacteriol (1966) 7.75
Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc Natl Acad Sci U S A (1990) 6.85
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol (1997) 5.60
Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem (1978) 5.43
Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci U S A (1993) 4.78
Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol (1979) 4.53
Further studies in the pyocine typing of Pseudomonas pyocyanea. J Med Microbiol (1969) 4.33
Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production. J Med Microbiol (1975) 4.09
Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet (1996) 4.07
Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol (2001) 4.02
Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother (1978) 3.97
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol (2000) 3.77
Alginate synthesis in mucoid Pseudomonas aeruginosa: a chromosomal locus involved in control. J Gen Microbiol (1980) 3.37
Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet (2001) 3.24
Classification of Alcaligenes faecalis-like isolates from the environment and human clinical samples as Ralstonia gilardii sp. nov. Int J Syst Bacteriol (1999) 2.52
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem (1989) 2.41
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 2.38
The instability of mucoid Pseudomonas aeruginosa: fluctuation test and improved stability of the mucoid form in shaken culture. J Gen Microbiol (1979) 2.31
Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet (1991) 2.27
Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol (2000) 2.20
Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology (1980) 2.18
Revised pyocin typing method for Pseudomonas aeruginosa. J Clin Microbiol (1984) 2.15
Isolation of alginate-producing mutants of Pseudomonas fluorescens, Pseudomonas putida and Pseudomonas mendocina. J Gen Microbiol (1981) 2.04
Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A (1985) 2.02
Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions. J Virol (1992) 2.02
Do all Pseudomonas cepacia produce carbapenemases? J Antimicrob Chemother (1993) 2.00
Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol (1981) 1.92
Mucoid Pseudomonas aeruginosa in cystic fibrosis: mutations in the muc loci affect transcription of the algR and algD genes in response to environmental stimuli. Mol Microbiol (1990) 1.85
Role of the far-upstream sites of the algD promoter and the algR and rpoN genes in environmental modulation of mucoidy in Pseudomonas aeruginosa. J Bacteriol (1990) 1.85
Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol (1995) 1.79
A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci U S A (1986) 1.78
Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine. Mol Pharmacol (1983) 1.75
Burkholderia fungorum sp. nov. and Burkholderia caledonica sp. nov., two new species isolated from the environment, animals and human clinical samples. Int J Syst Evol Microbiol (2001) 1.73
A promoter associated with the neisserial repeat can be used to transcribe the uvrB gene from Neisseria gonorrhoeae. J Bacteriol (1995) 1.68
Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother (1994) 1.68
Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins. Antimicrob Agents Chemother (1981) 1.66
Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol (1982) 1.55
Identification of Burkholderia species and genomovars from cystic fibrosis patients by AFLP fingerprinting. Int J Syst Bacteriol (1999) 1.53
Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect (1999) 1.50
Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun (1998) 1.47
Pyocine typing of mucoid strains of Pseudomonas aeruginosa isolated from children with cystic fibrosis. J Med Microbiol (1973) 1.44
Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett (1999) 1.41
Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). Antimicrob Agents Chemother (1987) 1.41
Typing of Pseudomonas cepacia by bacteriocin susceptibility and production. J Clin Microbiol (1985) 1.40
Pseudomonas cepacia--fatal pulmonary infection in a patient with cystic fibrosis. J Infect (1986) 1.40
Mucinophilic and chemotactic properties of Pseudomonas aeruginosa in relation to pulmonary colonization in cystic fibrosis. Infect Immun (1990) 1.39
Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol (1994) 1.39
Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem (1985) 1.33
Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother (1987) 1.24
Studies on the pyocins of Pseudomonas aeruginosa: morphology and mode of action of contractile pyocins. J Gen Microbiol (1974) 1.24
Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol Med Microbiol (1995) 1.24
Vitamin B 12 biosynthesis. Enzyme studies on the formation of the alpha-glycosidic nucleotide precursor. J Biol Chem (1969) 1.22
Mapping and characterization of two mutations to antibiotic supersusceptibility in Pseudomonas aeruginosa. J Gen Microbiol (1987) 1.16
Mouse beta defensin-1 is a functional homolog of human beta defensin-1. Mamm Genome (1998) 1.15
Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol (2001) 1.11
Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immun (1997) 1.11
A fatal transfusion reaction associated with blood contaminated with Pseudomonas fluorescens. Vox Sang (1988) 1.10
6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob Agents Chemother (1991) 1.09
Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med (1998) 1.07
In vivo significance of bacteriocins and bacteriocin receptors. Scand J Infect Dis Suppl (1986) 1.06
The pathogenic neisseriae contain an inactive rpoN gene and do not utilize the pilE sigma54 promoter. Gene (1998) 1.05
Absence of an SOS-like system in Neisseria gonorrhoeae. Gene (1998) 1.05
Kinetic properties and inhibition of orotidine 5'-phosphate decarboxylase. Effects of some allopurinol metabolites on the enzyme. J Biol Chem (1973) 1.05
Heterogeneity and reduction in pulmonary clearance of mucoid Pseudomonas aeruginosa. Rev Infect Dis (1984) 1.04
The pyocin Sa receptor of Pseudomonas aeruginosa is associated with ferripyoverdin uptake. J Bacteriol (1992) 1.03
Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. Antimicrob Agents Chemother (1987) 1.02
Burkholderia cepacia: another twist and a further threat. Thorax (1998) 1.01
Outbreak of subclinical mastitis in a flock of dairy sheep associated with Burkholderia cepacia complex infection. J Clin Microbiol (2001) 1.01
Burkholderia cocovenenans (van Damme et al. 1960) Gillis et al. 1995 and Burkholderia vandii Urakami et al. 1994 are junior synonyms of Burkholderia gladioli (Severini 1913) Yabuuchi et al. 1993 and Burkholderia plantarii (Azegami et al. 1987) Urakami et al. 1994, respectively. Int J Syst Bacteriol (1999) 1.00
Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob Agents Chemother (1995) 1.00
Antibiotic therapy and cystic fibrosis: increased resistance of mucoid Pseudomonas aeruginosa to carbenicillin. J Antimicrob Chemother (1976) 0.99
Neisseria gonorrhoeae contains multiple copies of a gene that may encode a site-specific recombinase and is associated with DNA rearrangements. Gene (1998) 0.99
3'-Azido-3'-deoxythymidine inhibits the replication of avian leukosis virus. J Virol (1987) 0.98
Acute magnesium poisoning as a complication of chronic intermittent haemodialysis. Br Med J (1968) 0.97
Long term transtracheal oxygen delivery through microcatheter in patients with hypoxaemia due to chronic obstructive airways disease. Br Med J (Clin Res Ed) (1986) 0.97
Studies on the pyocins of Pseudomonas aeruginosa: production of contractile and flexuous pyocins in Pseudomonas aeruginosa. J Gen Microbiol (1974) 0.96
Detection of Pseudomonas aeruginosa in sputum from cystic fibrosis patients by the polymerase chain reaction. Mol Cell Probes (1992) 0.94
Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J Virol (1991) 0.91
Transcriptional analysis of the groESL operon of Neisseria gonorrhoeae. Gene (1997) 0.90
Subspecific differentiation of Burkholderia cepacia isolates in cystic fibrosis. J Med Microbiol (1998) 0.90
Production and characterisation of mouse monoclonal antibodies reactive with the lipopolysaccharide core of Pseudomonas aeruginosa. J Med Microbiol (1992) 0.89
Burkholderia cepacia in cystic fibrosis. N Engl J Med (1995) 0.89
Mycobacterium ulcerans infections in two horses in south-eastern Australia. Aust Vet J (2010) 0.88
Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS Immunol Med Microbiol (1994) 0.88
Lipopolysaccharide chemotypes of Burkholderia cepacia. J Med Microbiol (1999) 0.87
Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J Med Microbiol (1993) 0.87
Ciprofloxacin therapy in cystic fibrosis. J Antimicrob Chemother (1987) 0.87
Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am J Med (1982) 0.87
Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect Immun (2005) 0.86
Incidence of common pyocin types of Pseudomonas aeruginosa from patients with cystic fibrosis and chronic airways diseases. J Med Microbiol (1990) 0.84